Manni Mohyuddin
@ManniMD1
Followers
13K
Following
11K
Statuses
8K
Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.
Salt Lake City, UT
Joined June 2020
RT @mwschoen: @ManniMD1 @OncologyCompany The survival of the control arm was less than contemporary trials of similar agents, which could b…
0
2
0
👌🏽👌🏽👌🏽 To say that belantamab does not impair quality of life is ridiculous. It speaks to the imperfection of how we assess and report quality of life. Unfortunate that some obvious truths have to be clearly pointed out this way. @AaronGoodman33
@AaronGoodman33 For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited
5
3
35
RT @shycollie: @AaronGoodman33 For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiti…
0
1
0
RT @oncology_bg: This is a pervasive problem. Why can’t journals ask for editorials from people who don’t get money from the same company w…
0
7
0
RT @rodneyanddelboy: @ManniMD1 I am left wondering what is the point of this editorial? I struggled to find any interesting analysis or ins…
0
1
0
This study (40 patients each arm) is a good representation of how a small sample size can lead to an unreliable estimate. A PFS difference of 13 months with ixazomib is unlikely to be replicated in phase 3, and inconsistent with what ixa has shown!
2
6
20
@rodneyanddelboy @OncologyCompany Most control arms get better and perform better over time, with improved supportive care/dosing strategies. I agree regarding CI, but a 3-4 months PFS diff is enough to lead to FDA approval! (Look at BOSTON/selinexor)!
1
0
1
@OncologyCompany I am perhaps not as trained as you in calling things as they should be called 😂 my point still stands!
1
0
2
RT @AaronGoodman33: Literally just about anyone would write an editorial if asked by NEJM. Can’t they find one doc to write the editorial w…
0
18
0
@OncologyCompany I disagree. In an unblinded study, censoring, attrition/withdrawal, and progression ascertainments all can play a role in generating a PFS estimate that isnt true.
2
0
5
RT @AaronGoodman33: Patients with myeloma are often over treated. Read our paper in Nature Reviews Clinical Oncology @DianaNrco
0
16
0
@TMSchmidtMD @AaronGoodman33 You can see the delta Dara maintenance had relative to doing nothing in CASSIOPEIA and it was trivial. Find if hard to believe Dara/len adds a whole lot more compared to Len in someone who got quad induction and already responded very well
0
0
0
Actually, Aaron has many papers/trials too. I am biased, but my favorite paper of his one we wrote together in which we highlighted the epidemic of over-treatment of myeloma and its precursor states. Heres a non paywalled link to it:
Happy to see this piece on @AaronGoodman33 in @TheLancetHaem. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is!
0
11
36
Happy to see this piece on @AaronGoodman33 in @TheLancetHaem. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is!
3
8
116